Nasus Pharma Ltd Dossier - Source-backed chat

Nasus Pharma Ltd

NSRXNYSE

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.81Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $44.7M

Enterprise Value $43.5M

Shares Outstanding 11.7M diluted

Moat Rating None

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nasus Pharma Ltd. (NYSE American: NSRX) is a clinical-stage specialty pharmaceutical company developing innovative powder-based intranasal (PBI) therapies for acute and life-threatening medical emergencies. The company's proprietary Nasax platform leverages uniform spherical powder particles to enable rapid, needle-free drug absorption through the nasal cavity's rich vascular network. The investment thesis is anchored on the clinical superiority demonstrated by its lead candidate, NS002 (intranasal epinephrine powder), which outpaced the standard-of-care EpiPen in Phase 2 trials. With a successful $15 million private placement in February 2026, the company has secured its cash runway through Q2 2027, fully funding its upcoming pivotal study in Q4 2026. At a sub-micro-cap valuation, Nasus offers an asymmetric risk-reward profile compared to approved needle-free competitors like ARS Pharmaceuticals' Neffy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$19.67

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

The bear case reflects clinical or regulatory delays in initiating the NS002 pivotal study, or a failure to replicate the Phase 2 pharmacokinetic advantages in the larger pivotal cohort. Furthermore, if the company fails to secure additional funding beyond its Q2 2027 runway, the going concern risk highlighted by auditors will intensify, leading to highly dilutive equity financing or a halt in pipeline expansion.

Base CaseCentral scenario

$18.0060%

The base case assumes Nasus successfully initiates its NS002 pivotal study in Q4 2026 and delivers positive top-line results in Q1 2027 that confirm the Phase 2 pharmacokinetic advantages (faster absorption and higher early exposure than EpiPen). It also assumes the successful initiation of the NS003 Phase 1 trial in Q3 2026. Under this scenario, the company's proprietary Nasax platform is further validated, positioning Nasus for a potential NDA submission in late 2027 and attracting institutional coverage or partnership interest.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Technology: The proprietary Nasax powder-based intranasal platform offers superior nasal deposition, stability, and faster absorption compared to liquid nasal sprays and traditional autoinjectors.
Strong Phase 2 Clinical Data: NS002 achieved a median time to the critical 100 pg/mL epinephrine threshold of 1.69 minutes compared to 3.42 minutes for EpiPen (p=0.033), with 88.4% of subjects reaching the threshold at 5 minutes versus 64.6% for EpiPen.
Secured Near-Term Runway: The $15 million private placement closed in February 2026 extends the company's cash runway through Q2 2027, covering the pivotal study of NS002 and early clinical milestones for NS003.
Asymmetric Valuation: Trading at a market capitalization of approximately $34 million, Nasus represents a high-potential play on the rapidly growing needle-free emergency medicine market, currently validated by ARS Pharmaceuticals' near-billion-dollar valuation.

Key Investment Risks

Clinical and Regulatory Uncertainty: NS002 must still successfully complete a pivotal trial and obtain FDA approval, with no guarantee that pivotal data will match Phase 2 results.
Going Concern and Funding Risk: The company has an accumulated deficit of $18.5 million as of December 31, 2025, and will require an estimated $18–$22 million in additional capital to fully execute its long-term business plan and achieve commercialization.
Single-Asset Concentration: The company's near-term valuation is heavily dependent on NS002, as other pipeline candidates (NS003, NS004, NS005) are in preclinical or early clinical stages, and work on NS001 (naloxone) is currently paused.

Thesis Invalidation Triggers

Failure to initiate the NS002 pivotal study by the end of Q4 2026 due to regulatory or manufacturing delays.
Pivotal study results for NS002 failing to demonstrate bioequivalence or pharmacokinetic superiority/non-inferiority to EpiPen.
Inability to secure additional financing or strategic partnerships by early 2027, leading to severe liquidity constraints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.